. Author manuscript; available in PMC: 2014 Nov 15.

Published in final edited form as: J Immunol. 2013 Oct 9;191(10):10.4049/jimmunol.1300467. doi: 10.4049/jimmunol.1300467

Table II.

gp100_44–59 APLs and their affinity for HLA-DR4

gp100_44–59 and APLs	Amino acid sequence	Substituted position	IC50 (nM)
WT	WNRQLYPEWTEAQRLD	NA	627
L48F	----F-----------	P1^*	280
Y49M	-----M----------	P2	521
P50A	------A---------	P3	189
E51A	-------A--------	P4^*	199
E51Q	-------Q--------	P4^*	200
W52A	--------A-------	P5	372
T53V	---------V------	P6^*	489
E54L	----------L-----	P7^*	65
E54T	----------T-----	P7^*	104
A55G	-----------G----	P8	553
Q56A	------------A---	P9^*	276
Q56I	------------I---	P9^*	926

Indicates MHC anchor residues according to crystal structure. IC50, 50% inhibitory concentration. WT, wild type gp100 peptide sequence. NA, not applicable.